Standout Papers

A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy 2023 2026 202482
  1. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy (2023)
    Mohit Mathur, Jonathan Barratt et al. New England Journal of Medicine

Citation Impact

4 standout
Sub-graph 1 of 2

Citing Papers

The WHO fungal priority pathogens list: a crucial reappraisal to review the prioritisation
2024 Standout
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy
2024 Standout
2 intermediate papers

Works of Mohit Mathur being referenced

MO258SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF VIS649, AN APRIL-NEUTRALIZING IGG2 MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY
2021
Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation
2019

Author Peers

Author Nephrology Epidemiology Hematology Rheumatology Last Decade Papers Cites
Mohit Mathur 166 116 54 61 37 307
S. Geetha 31 321
Hope A. Flaxman 12 38 10 261
M Lenziardi 8 15 1 7 10 328
David Rodrick 7 2 1 23 235
Kazimierz Dąbrowski 2 15 350

All Works

Loading papers...

Rankless by CCL
2026